- Home
- GHRS
GHRS
GH Research PLC
as 02-21-2025 4:00pm EST
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
Upcoming Earnings Alert:
Get ready for potential market movements as GH Research PLC GHRS prepares to release earnings report on 27 Feb 2025.
| Founded: | 2018 | Country: | Ireland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 868.7M | IPO Year: | 2021 |
| Target Price: | $35.67 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.00 - $20.50 | Next Earning Date: | 02-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest GH Research PLC News
GHRS Breaking Stock News: Dive into GHRS Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
Cantor Fitzgerald Initiates GH Research at Overweight
Simply Wall St.
13 days ago
GH Research PLC's (NASDAQ:GHRS) Top Key Executive Florian Schonharting is the most upbeat insider, and their holdings increased by 31% last week
Zacks
16 days ago
GHRS Stock Rallies 55% in a Week: Here's What You Should Know
GlobeNewswire
18 days ago
GH Research Announces Pricing of $150 Million Public Offering
Insider Monkey
19 days ago
Why GH Research PLC (GHRS) Is Skyrocketing So Far In 2025
MT Newswires
19 days ago
GH Research Launches $150 Million Public Offering
GlobeNewswire
19 days ago
GH Research Announces Proposed Public Offering
MT Newswires
19 days ago
Top Premarket Gainers
Compare GHRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GHRS GH Research PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.